Donald Trump may have convinced the US pharma giant Pfizer to defer a price increase for dozens of drugs, but there are others that have escaped such intense scrutiny according to a report.
Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.
As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson & Johnson (J&J) and US private equity firm Platinum Equity over the sale of the